HENDERSON, Nev. ,
March 20,
2024 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,
has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd
("Fujifilm Vet Systems"), a leading veterinary diagnostic
laboratory service, to launch the Nu.Q® Vet Cancer Test to
veterinarians in Japan.
Volition's supply agreement enables Fujifilm Vet Systems to sell
and perform cancer screening services for dogs using the Nu.Q® Vet
Cancer Test throughout its network of central reference
laboratories in Japan. The
Nu.Q® Vet Cancer Test is an accessible and
affordable screening tool for dogs to aid in early cancer
detection.
Dr. Tom Butera, Chief Executive
Officer, Volition Veterinary Diagnostics Development LLC said: "We
are thrilled to be expanding into the Japanese market with Fujifilm
Vet Systems. It is the country's leading veterinary diagnostic
laboratory service with a network of ten laboratories, supplying
veterinary clinics and hospitals nationwide.
"Through Fujifilm Vet Systems, Japanese veterinarians will have
access to a cutting-edge test to help detect cancer in its early
stages, leading to better outcomes and improved patient care. Our
Nu.Q® Vet Cancer Test is a simple, easy-to-use, blood screening
test that can be easily integrated into preventive care programs
and used alongside other routine bloodwork during regular wellness
visits."
Dr. Jasmine Kway, Chief Executive
Officer of Singapore Volition added:
"Japan is a considerable market
opportunity for Volition, as we seek to expand our Nu.Q® Vet Cancer
Test offering in Asia. We look
forward to working alongside Fujifilm Vet Systems as they roll out
our test countrywide, across their diagnostic laboratory
network."
Kiyotaka Fujiwara, Chief
Operating Officer at Fujifilm Vet Systems, said: "We are delighted
to add the Nu.Q® Vet Cancer Test to our diagnostic service
portfolio and expand our wellness testing offer to Japanese
veterinarians. We will notify our customers as soon as the test is
available for purchase."
About Volition
Volition is a multi-national epigenetics company focused on
advancing the science of epigenetics. Volition is dedicated to
saving lives and improving outcomes for people and animals with
life-altering diseases through earlier detection, as well as
disease and treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore. Volition's subsidiary,
Belgian Volition SRL is the party to the supply agreement with
Fujifilm Vet Systems.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is
included in this document as an inactive textual reference
only.
About FUJIFILM VET Systems
FUJIFILM VET Systems provides testing services centered on
health checkups to veterinary medical facilities nationwide. We can
also handle specialized examinations that cannot be performed at
veterinary hospitals. In addition, we have established contract
laboratories at 10 bases in Japan,
and we have led the market by providing services that quickly
report test results by utilizing our testing network and specimen
collection network. Veterinarians at veterinary hospitals and
clinics nationwide have praised its promptness and convenience.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's estimated market
opportunity, the effectiveness of Volition's blood-based
diagnostic, prognostic and disease monitoring tests, and Volition's
ability to develop and successfully commercialize such test
platforms for early detection of cancer and other diseases as well
as serving as a diagnostic, prognostic or disease monitoring tools
for such diseases. Volition's actual results may differ materially
from those indicated in these forward-looking statements due to
numerous risks and uncertainties, including, without limitation,
results of studies testing the efficacy of its tests. For instance,
if Volition fails to develop and commercialize diagnostic,
prognostic or disease monitoring products, it may be unable to
execute its plan of operations. Other risks and uncertainties
include Volition's failure to obtain necessary regulatory
clearances or approvals to distribute and market future products; a
failure by the marketplace to accept the products in Volition's
development pipeline or any other diagnostic, prognostic or disease
monitoring products Volition might develop; Volition's failure to
secure adequate intellectual property protection; Volition will
face fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks
identified in Volition's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as other documents that
Volition files with the Securities and Exchange Commission. These
statements are based on current expectations, estimates and
projections about Volition's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/volition-and-fujifilm-vet-systems-launch-nuq-vet-cancer-test-in-japan-302094498.html
SOURCE VolitionRx Limited